By Pauline Anderson
The US Food and Drug Administration (FDA) has approved the Algovita Spinal Cord Stimulation System (Greatbatch Inc), a device to treat chronic pain, the company announced in a press release.
The device is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain. 
Greatbatch also announced that it is in the process of finalizing the proposed spin-off of QiG Group, LLC, which will be renamed Nuvectra Corporation. Since its inception in 2008, QiG Group has developed an innovative, broad-based, neurostimulation technology platform, the company notes in a statement issued November 30.
Initially, the company will focus on the commercialization of the Algovita SCS system, it said.